Literature DB >> 18516924

Primary choriocarcinoma of the urinary bladder.

Sadatsugu Minei1, Tsuyoshi Matsui, Daisuke Obinata, Kenya Yamaguchi, Daisaku Hirano, Satoru Takahashi.   

Abstract

A 72-year-old woman with asymptomatic macrohematuria was referred to our hospital. Cystoscopy revealed a 7 cm sessile tumor on the left lateral wall of the bladder. Subsequently an intravenous pyelography revealed left hydronephrosis. We performed transurethral biopsy and resection of the bladder tumor under the diagnosis of ordinary malignant bladder tumor. Histopathologically, the lesion was shown to be an undiffentiated urothelial carcinoma, G3, > or = pT2, containing syncytiotrophoblastic giant cells. The level of serum human chorionic gonadotropin-beta (hCG-beta) level was slightly elevated (0.3 ng/ml; normal value: < 0.1). Because a further examination revealed an invasion into the surrounding fat tissue of the bladder and left ureter, a total cystohysterectomy with an ileal conduit were performed. The final histopathological classification was choriocarcinoma of the urinary bladder, pT3a, pN1, pMx. An adjuvant combination chemotherapy was carried out using methotrexate, vinblastine, adriamycin and cisplatin (MVAC). After two courses of chemotherapy, the serum hCG-beta levels returned to normal. Eleven months postoperatively, however, there was evidence of multiple lung metastases. The patient died 12 months after the surgery as a result of complications caused by widespread metastases.

Entities:  

Mesh:

Year:  2008        PMID: 18516924

Source DB:  PubMed          Journal:  Hinyokika Kiyo        ISSN: 0018-1994


  2 in total

1.  GATA-3 expression in primary pure choriocarcinoma of the bladder.

Authors:  Mayuka Shinohara; Toshitaka Shin; Tsutomu Daa; Hiromitsu Mimata
Journal:  IJU Case Rep       Date:  2020-02-20

2.  Primary choriocarcinoma of the liver: a clinicopathological study of five cases in males.

Authors:  Huaiyin Shi; Dengfeng Cao; Lixin Wei; Lu Sun; Aitao Guo
Journal:  Virchows Arch       Date:  2009-12-16       Impact factor: 4.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.